BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
See today's BioWorld
Home
» Abraxis Reports Good NSCLC Results; Pancreatic Data Pending
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Abraxis Reports Good NSCLC Results; Pancreatic Data Pending
March 18, 2010
By
Catherine Hollingsworth
No Comments
Abraxane combined with carboplatin was shown to be superior to Taxol plus carboplatin in terms of overall response rate in a Phase III study in patients with non-small-cell lung cancer (NSCLC), Abraxis BioScience Inc. reported. (BioWorld Today)
BioWorld